Oshkosh Corporation Recognized as One of the World's Most Ethical Companies for Tenth Consecutive Year
OSHKOSH, Wis., March 11, 2025--(BUSINESS WIRE)--Oshkosh Corporation (NYSE: OSK), a leading innovator of purpose-built vehicles and equipment, announced today it has been recognized by Ethisphere, a global leader in defining and advancing the standards of ethical business practices, as one of the 2025 World's Most Ethical Companies®. This marks the company's 10th consecutive recognition. Oshkosh is among 136 honorees spanning 19 countries and 44 industries.
The World's Most Ethical Companies assessment is grounded in Ethisphere's proprietary Ethics Quotient®, which requires companies to provide more than 240 different proof points on practices that support robust ethics and compliance, governance, a culture of ethics, environmental and social impact; and initiatives that support a strong value chain. That data undergoes further qualitative analysis by Ethisphere's panel of experts who spend thousands of hours vetting and evaluating applicants.
"We are honored to be recognized as one of the World's Most Ethical Companies for the 10th consecutive year," said Ignacio A. Cortina, executive vice president, chief legal and administrative officer, Oshkosh Corporation. "This achievement reflects our unwavering commitment to integrity, ethical leadership and responsible business practices across our global operations. We are dedicated to a culture where ethics and values guide every decision we make."
In addition to being recognized as one of the World's Most Ethical Companies by Ethisphere, Oshkosh is listed on Fortune's World's Most Admired Companies 2025 list, named to the 2024 Dow Jones Sustainability World Index (DJSI World), is on Newsweek's America's Most Responsible and one of the World's Most Trustworthy Companies list and is among those on USA Today's list of America's Climate Leaders 2024.
To learn more about Oshkosh Corporation, its values and commitment to doing the right thing, click here.
About Oshkosh Corporation
At Oshkosh (NYSE: OSK), we make innovative, mission-critical equipment to help everyday heroes advance communities around the world. Headquartered in Wisconsin, Oshkosh Corporation employs over 18,000 team members worldwide, all united behind a common purpose: to make a difference in people's lives. Oshkosh products can be found in more than 150 countries under the brands of JLG®, Pierce®, MAXIMETAL, Oshkosh® S-Series™, Oshkosh® Defense, McNeilus®, IMT®, Jerr-Dan®, Frontline™ Communications, Oshkosh® Airport Products, Oshkosh AeroTech™ and Pratt Miller. For more information, visit oshkoshcorp.com.
®, ™ All brand names referred to in this news release are trademarks of Oshkosh Corporation or its subsidiary companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250311102014/en/
Contacts
For more information, contact:
Financial:Patrick DavidsonSenior Vice President, Investor Relations920.502.3266
Media:Tim GilmanSenior Manager, Communications and Branding920-509-0617
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
17 minutes ago
- CNBC
The biggest risk to valuations is what happens to 10-year rates, says Barclays' Venu Krishna
Venu Krishna, Barclays head of U.S. Equity Strategy, joins 'The Exchange' to discuss Barclays lifting it S&P target to 6,050.
Yahoo
17 minutes ago
- Yahoo
Telix Pharmaceuticals (ASX:TLX) Gains Portugal Approval for Illuccix in Prostate Cancer Detection
Telix Pharmaceuticals recently gained marketing authorization for its prostate cancer imaging agent, Illuccix®, in Portugal. This development enhances diagnostic options in a country where prostate cancer is prevalently diagnosed. Last week, the company's share price rose by 3%, a move that aligns with its recent regulatory success. Although the broader market remained steady over the same period, Telix's approval could provide additional support to its stock performance. The growth in Telix's share price complements the longer-term market trend, with broader market earnings expected to grow annually, positioning the company favorably. We've discovered 1 risk for Telix Pharmaceuticals that you should be aware of before investing here. We've found 20 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Over the past five years, Telix Pharmaceuticals has delivered a tremendous total shareholder return of 1863.90%. In the past year, Telix's performance surpassed the Australian Biotechs industry, which saw a 10.2% decline, highlighting the company's robust and resilient market position. The recent marketing authorization for Illuccix® in Portugal is expected to bolster revenue streams, complementing the company's efforts to expand its presence across international markets. These developments align with revenue forecasts expecting annual growth of 19.5%, outpacing the broader Australian market's expected growth of 5.6% annually. Telix's earnings forecasts also suggest promising growth, projected to rise significantly at 33.2% per year, compared to the market's 11.7%. This is supported by the company's strategic approvals and existing product portfolio, contributing to upward earnings revisions. The current share price movement, slightly below the consensus analysts' price target of A$32.05, suggests that there may be potential for further share price appreciation as the company continues to execute its growth strategy. The recent developments reinforce investor confidence in Telix's ability to sustain its growth trajectory in a competitive industry landscape. Gain insights into Telix Pharmaceuticals' past trends and performance with our report on the company's historical track record. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:TLX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
CNBC
17 minutes ago
- CNBC
Health care stocks are due for a turnaround after a historically bad month, according to the charts
The Health Care Select Sector SPDR Fund (XLV) was down over 5% in May, as the S & P 500 gained over 6%, which means that XLV underperformed the index by 11%. That's a huge performance discrepancy. In fact, it was the worst relative monthly percent move vs. the SPX in XLV's history, dating back to late 1998. As is clear from this long-term chart, the odds of this horribly bad relative weakness continuing at this same pace is low – at least for June. XLV itself now has approached two major long-term support levels after the recent downturn. The first is the rising trendline that begins at the 2009 financial crisis low and extends through the Covid bottom. XLV tested this line in mid-May, bounced and finished the month modestly off its lows. The second key support zone comes from the cluster of lows in 2021, 2022 and 2023, noted by the horizontal line that's in the low 120s. The converging lines present a confluence of support that clearly could help XLV's bouncing prospects in June. XLV: The 3 biggest holdings Believe it or not, 34 of XLV's 61 components actually logged gains in May. That's encouraging, but we'll need to see its biggest holdings respond soon. If they can't rally, XLV will continue to struggle. The three largest stocks within the ETF are Eli Lilly , Johnson & Johnson and AbbVie , which make up nearly 27% of XLV combined. So, what are the odds that all three stocks actually can mount strong up-moves in June? Let's take a closer look. We'll start with LLY since it's XLV's biggest component, with a 12% weighting. LLY last made an all-time high in August 2024. From that peak to its April low, the stock lost 30%. But as the following weekly chart (in log scale) shows, it wasn't straight down from there. LLY logged various rallies and drawdowns since then, all of which have taken place within the pictured downward sloping trading channel. The best time to buy LLY, thus, has been after a big, long decline. The stock just fell another 20% from April 30 through May 25. As we can see, the past ensuing bounces yielded big percentage moves, even if they ultimately failed to break through the channel's upper threshold. Additionally, LLY's weekly Williams %R indicator (on the lower panel) is emerging from an oversold condition, which has supported three of the last four big up-moves. In fact, LLY quietly has logged gains in six of the last seven trading days. That's a good start. JNJ (7.7% weight) has been trending lower since topping in 2022, while ABBV (6.8%) has been in a clear uptrend the last few years. However, both have experienced various swings within their respective long-term trading channels — like LLY. And with both JNJ and ABBV having sold off from their 2025 highs, now would be an opportune time for the next bounce to commence. From a big picture market perspective, rotation is an important component of true, long-lasting uptrends. Thus, if/when the air comes out of the more extended sectors and groups soon, capital could find its way to the underperforming areas, which of course, includes health care. DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
